Sensyne licenses MagnifEye technology to Excalibur
Sensyne Health licenses MagnifEyeÔ technology to Excalibur Healthcare Services for use with lateral flow diagnostic tests
· Immediate application for global COVID-19 antigen testing with the capacity to process up to 1.1 billion tests per year
· Excalibur will integrate MagnifEye into its lateral flow products for global marketing to customers in both the public and private sectors
· Agreement provides royalties to Sensyne on each test result with a minimum guaranteed contract value and affords exclusivity to Excalibur for all lateral flow applications
· Future applications include Excalibur's new lateral flow cancer biomarker diagnostics currently in development
Oxford, U.K. 09 February 2021: Sensyne Health plc (LSE: SENS) ("Sensyne" or the "Company" or the "Group"), the UK Clinical AI company, today announces that it has signed an exclusive licence and development agreement with Excalibur Healthcare Services Limited ("Excalibur") to apply Sensyne's MagnifEye system for use with Excalibur's proprietary lateral flow rapid diagnostic tests across a range of indications including its COVID-19 antigen test currently being marketed in the UK and across Europe. In recent trials, the Excalibur COVID-19 antigen lateral flow diagnostic test has out-performed other competing lateral flow tests with its speed, sensitivity and reliability. The test has been approved by the UK regulator for mass population screening in symptomatic and asymptomatic people.
The MagnifEye system ("the System") is Sensyne's proprietary software application available as both a smartphone app and a web application, that uses a cloud-based deep learning algorithm to automate the reading and analysis of different diagnostic tests including lateral flow tests. The System has been adapted to Excalibur's already high-performance lateral flow Antigen test. The System trains users to administer a lateral flow test, then interpret that test and provide a shareable digital certificate that validates the training of the user, the test result and resulting health status. It is anticipated that this will facilitate frequent testing, both for COVID-19 and a range of other conditions.
Excalibur will market the System alongside its current and future portfolio of lateral flow tests globally to customers in both the public and private sectors, with Sensyne acting as its critical clinical AI technology supplier, underpinning each new product. Excalibur will pay Sensyne a royalty each time the System is used to read a lateral flow test with a minimum guaranteed royalty sum of £4.8 million payable over the first two years of the agreement. The analytical capacity of the System at launch will match Excalibur's current lateral flow test manufacturing capacity of approximately three million tests per day (approx. 1.1 billion test per year).
The initial focus will be on use of MagnifEye for COVID-19 antigen testing, followed by its potential application in new lateral flow diagnostic tests for serology, cancer and other disease conditions that Excalibur is currently developing. Beyond this agreement, Excalibur and Sensyne will seek to collaborate on the development of further projects that combine Excalibur's expertise in the development and marketing of high-quality diagnostic tests with Sensyne's expertise in the development and supply of software systems using clinical AI.
Lord (Paul) Drayson PhD, CEO of Sensyne Health, said:
"The combination of Sensyne's clinical AI technology and Excalibur's test will, we believe, provide the most accurate diagnostic lateral flow test available in the world today. This agreement reflects the UK's leadership position and expertise in life science and data science and underlines Sensyne's expertise in putting the AI inside a growing range of innovations. With increasing global demand for rapid, easy to use diagnostic testing across a range of conditions, this agreement has the potential to create significant value from this fast growing $6 billion market. Sir Chris's team at Excalibur has been established for more than 20 years and we are delighted to be working with them."
Professor Sir Chris Evans, Chairman and CEO of Excalibur Healthcare Services, said:
"Through our laboratories in Cambridge, we have been working with Sensyne to optimise the application of MagnifEye with our rapid antigen COVID test. The combination has significantly increased the sensitivity of the test and we believe makes it the most advanced and accurate antigen lateral flow test in the worldwide market today. This is another triumph for UK science and technology.
"Whereas nearly all lateral flow antigen tests pick up viral loads at an approximate Ct25 level as visually readable coloured bands, we have now dramatically increased the sensitivity of our test by over 50%, picking up positive results in the Ct range of 29-30, which are invisible to the naked eye. This increased sensitivity means our test can now detect positives across the entire range of infectious COVID viral loads."
For more information please contact:
Sensyne Health (www.sensynehealth.com)
+44 (0) 330 058 1845
Lord (Paul) Drayson PhD FREng, Chief Executive Officer
Michael Norris, Interim Chief Financial Officer
Dr Richard Pye, Chief Investment Officer
Peel Hunt LLP (Nominated Adviser and Joint Broker)
+ 44 (0) 20 7418 8900
Dr Christopher Golden
Liberum (Joint Broker)
+ 44 (0) 20 3100 2000
Consilium Strategic Communications
+44 (0) 20 3709 5700
Excalibur Healthcare Services
+44 (0) 7788 414856
About Sensyne Health www.sensynehealth.com
Sensyne Health plc is a clinical AI company that works in partnership with the NHS to improve patient care and accelerate the discovery and development of new medicines. Sensyne Health is listed on the AIM Market of the London Stock Exchange (SENS.L).
About Excalibur Healthcare Services www.excaliburhealth.co.uk
Excalibur Healthcare Services Limited is an international company specialising in the development and provision of high-quality medical products and services. The company is led by Professor Sir Christopher Evans, OBE, one of Europe's foremost biosciences, medical and healthcare entrepreneurs and caters for the needs of healthcare institutions, commercial organisations and individual customers. Excalibur is also involved in clinical trials, innovative product development and advanced diagnostic services.
Excalibur's rapid SARS COV-2 Antigen Screening test is the first ever lateral flow antigen test to receive regulatory approval for use in mass screening for COVID-19 in asymptomatic, pre-symptomatic and symptomatic populations. Since regulatory approval in October 2020 Excalibur and its manufacturing partner, Boson, have sold more than 20 million tests to over 700 public and private sector customers.
 A high cycle threshold (Ct) indicates a low concentration of viral genetic material which is typically associated with a lower risk of infectivity.